Ernexa Therapeutics (NASDAQ:ERNA) Posts Earnings Results, Misses Expectations By $5.00 EPS

Ernexa Therapeutics (NASDAQ:ERNA) posted its quarterly earnings results on Wednesday. The company reported ($6.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00), FiscalAI reports.

Ernexa Therapeutics Stock Down 0.4%

ERNA opened at $11.40 on Thursday. The firm has a market capitalization of $13.34 million, a P/E ratio of -0.44 and a beta of 1.88. The stock’s 50 day moving average price is $6.52 and its two-hundred day moving average price is $19.70. Ernexa Therapeutics has a 12-month low of $3.18 and a 12-month high of $93.75.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ERNA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Brookline Capital Markets started coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They set a “buy” rating and a $30.00 price target for the company. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Finally, Wall Street Zen raised Ernexa Therapeutics to a “hold” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $30.00.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.